Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT06458803 |
Other study ID # |
TJ-IRB202404119 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
May 6, 2013 |
Est. completion date |
November 19, 2023 |
Study information
Verified date |
June 2024 |
Source |
Tongji Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Immune thrombocytopenia (ITP) is a haemorrhagic disorder often associated with CTD.
Corticosteroids are the first-line treatment for CTD-associated thrombocytopenia, but not all
patients respond well. Eltrombopag is an oral, small molecule thrombopoietin receptor
agonist. It interacts with the transmembrane domain of the thrombopoietin receptor and
stimulates platelet production. This study is designed to evaluate the efficacy and safety of
eltrombopag in patients with refractory CTD-ITP. It is a single-centre, retrospective,
observational study involving a cohort of 52 patients diagnosed with CTD-RITP who received
eltrombopag between 2013 and 2023. Follow-up data will be systematically collected and
analysed to evaluate the therapeutic efficacy and safety of the drug. The study will provide
valuable insight into the benefit of eltrombopag in CTD-RITP by reviewing baseline
characteristics and performing subsequent clinical assessments to determine drug response and
adverse events.
Description:
Immune thrombocytopenia (ITP) is a hemorrhagic disorder typically attributed to the formation
of autoantibodies against platelet antigens. Patients experience decreased platelet count,
clinically presenting as purpura, petechiae, mucosal bleeding, and increased menstrual
bleeding. ITP is often associated with connective tissue diseases (CTD), with reports
indicating a concurrent presence of ITP in 10%-15% of systemic lupus erythematosus (SLE)
patients and 7.8% of primary Sjögren's syndrome (SS) patients.
Currently, corticosteroids are the first-line therapy for CTD-associated thrombocytopenia,
with second-line options including immunosuppressive agents, intravenous immunoglobulin
(IVIG), splenectomy, and rituximab. However, not all patients respond favorably to these
treatments. Patients with CTD who are unresponsive or have a low response to conventional
first- and second-line therapies, with platelet counts below 30×10^9/L, are considered to
have CTD-related refractory ITP (RITP). There are currently no internationally unified
diagnostic criteria for RITP. For adult RITP diagnosis, criteria proposed by George et al.
include: being diagnosed with ITP under the premise that treatment with glucocorticoids
and/or splenectomy is ineffective; age ≥18 years; ③ duration of illness >6 months; ④ absence
of other conditions causing thrombocytopenia; ⑤ platelet count ≤30×10^9/L.
Eltrombopag is an oral, small-molecule, non-peptide thrombopoietin receptor agonist that
interacts with the transmembrane domain of the thrombopoietin receptor, stimulating platelet
production and increasing platelet counts. To evaluate the efficacy and safety of eltrombopag
in CTD-RITP, this study will conduct a single-center retrospective observational analysis of
52 patients with CTD-RITP who received eltrombopag treatment between 2013 and 2023, recording
their follow-up information. Patient characteristics at baseline will be analyzed, and drug
efficacy and safety will be assessed through follow-up examinations at different time points.
During treatment, patients may receive other ITP medications for maintenance therapy (such as
glucocorticoids, azathioprine, danazol, cyclosporine A, and mycophenolate mofetil), excluding
those concurrently using other TPO receptor agonists. Patient follow-up examinations will be
continuously recorded (for at least six months, with monthly records, and patients followed
until the last follow-up time if less than six months). Univariate analysis (descriptive
analysis or non-parametric tests), single and multiple logistic regression analysis, and
multiple correspondence analysis (MCA) will be used to analyze early clinical predictive
factors for drug response. Patient drug responsiveness will be judged based on laboratory
test results and clinical symptoms: ① Complete remission (CR): PLT ≥100×10^9/L with no
bleeding tendency; ② Partial remission (PR): PLT ≥50×10^9/L but <100×10^9/L with no bleeding
tendency, or platelet count at least twice that of pre-treatment; ③ No remission (NR): Does
not meet criteria ① or ②. Mann-Kendall test will be used to analyze trends in PLT changes
among patients during treatment, and the rates of CR, PR, and NR at different time points (4,
8, 12, 24 weeks) will be calculated to determine drug onset time and remission degree. The
incidence of major adverse reactions to eltrombopag (hepatotoxicity, thrombosis) will be
statistically analyzed at 24 weeks to assess drug safety.
This project aims to evaluate the efficacy and safety of eltrombopag in treating CTD-RITP
patients, providing evidence for formulating treatment plans for CTD-RITP patients. It aims
to guide physicians in considering the use of eltrombopag when selecting treatment methods,
understanding individual differences in patient response to eltrombopag efficacy, and helping
physicians develop more personalized treatment plans based on early clinical predictive
factors to improve treatment targeting and effectiveness. Furthermore, it aims to observe the
long-term effects of eltrombopag treatment and explore the optimal dosage, course of
treatment, and best combination therapy with other drugs.